This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Teshima T , Hanlon AM , Hanks GE
Pretreatment Prostate-Specific Antigen Values in Patients, with Prostate-Cancer - 1989 Patterns of Care Study Process Survey
International Journal of Radiation Oncology Biology Physics. 1995 Nov 1;33(4) :809-814
AbstractPurpose: A Patterns of Care Study (PCS) national survey was conducted to show the national averages for processes of radiation therapy care for prostate cancer patients in 1989, In the current study we report an analysis of pretreatment prostate-specific antigen (PSA) by stage, grade, and ethnic origin. Methods and Materials: Process data were collected from 672 patients treated in 1989 at 71 separate institutions, Four hundred and twenty-seven (64%) of these patients had a pretreatment PSA value recorded, Three hundred and forty-three of the 427 patients were treated with external beam irradiation alone and were selected for the current analysis, The 1992 AJCC staging system was used. Results: There was a significant increase in pretreatment PSA with increasing stage, The median values of PSA were 8.3 ngm/ml in the T1 group (n = 65), 11.2 ngm/ml in the T2 group (n = 178), and 20.9 ngm/ml in the T3 group (n = 90) (p < 0.001), Ten patients were not staged, There was a significant increase in pretreatment PSA with decreasing differentiation. The median pretreatment PSA was 9.7 ngm/ml in well-differentiated tumors (n = 109), 13.0 ngm/ml in moderately differentiated tumors (n = 163), and 22.0 ngm/ml in poorly differentiated tumors, (n = 61) (p < 0.001), Ten patients had no differentiation recorded, African Americans (24) showed a significant increase in pretreatment PSA compared to Caucasians (304), The respective medians were 23.2 ng/ml and 11.9 ng/ml (p = 0.04). They also show more poorly differentiated tumors (33% vs, 17%) and more T3 tumors (46% vs, 25%), Other minorities, although small in number (n = 9) were similar to African Americans. Conclusion: Pretreatment PSA levels were established for patients treated with external beam irradiation in 1989 in the United States, They increase with stage and decreasing differentiation, African Americans and other minorities show a doubling of median values compared to Caucasians' pretreatment PSA with an increase in stage and grade. The adverse prognosis observed for African Americans is predicted by their pretreatment PSA, The cause of this PSA elevation is not known and may be related to lack of access to care or to a more aggressive biology for prostate cancer in African Americans.
NotesTimes Cited: 10 Article TE826 INT J RADIAT ONCOL BIOL PHYS